Ionis Cuts Trygolza Price Ahead Of Big New Indication
Peak sales predictions are rising after Ionis lowered the list price of Tryngolza in its initial rare disease indication ahead of US FDA approval in the larger severe hypertriglyceridemia market.
Scrip - March 26, 2026

Deal Watch: Pulmatrix Finds New Merger Partner In Eos Senolytix
Also, Insilico’s pacts with Tenacia and Aska, plus deals involving Merck & Co./Quotient, Yatiri/Oscotec, Everest/Corxel, GlycoNex/Nippon Kayaku, G2G/Samsung, Alebund/R1 and more.
Scrip - March 26, 2026

Takeda Plans JPY200bn In Cost Cuts To Offset Launch Investments
The company said it would streamline corporate functions to offset spending on multiple launches this year, including oveporexton, rusfertide and zasocitinib.
Scrip - March 26, 2026

LSI Panel: Investors, Medtech Leaders Expect M&A Rebound In 2026, But Only For Strong Assets
Medtech leaders expect dealmaking to rebound in 2026, but buyers are more selective. Buyers are focused on high-value assets, and AI must prove real clinical and commercial value.
Medtech Insight - March 26, 2026

No Subscription, No Compromise: Ultrahuman Returns To US Market With Ring Pro To Take On Oura
Ultrahuman is back in the US – five months after a patent ruling forced it out. The Ring Pro is redesigned, the pricing model is subscription-free, and the market it is returning to has more competition than the one it left. The real test starts May 15.
Medtech Insight - March 26, 2026

How The Kelun-Merck Pact Shaped Future Of China Dealmaking
The days of the "China discount" look numbered and more strategic partnerships have emerged following the landmark deal, said panelists at BIO-Europe Spring in Lisbon.
Scrip - March 26, 2026

Symrise Prioritizes Health & Beauty With New Division
German chemicals company responding to consumer demand for products supporting healthier longevity with new Care & Wellness division.
HBW Insight - March 26, 2026

AI Act Amendments Bring Relief Not Resolution
Industry association MedTech Europe has welcomed amendments to the AI Act that delay and simplify rules for AI medical devices, but more work still needs to be done on clarity, coherence and system implementation.
Medtech Insight - March 26, 2026

Medtronic Takes On Boston Scientific In Back Pain With ViaVerte BVNA Deal
Medtronic is entering the basivertebral nerve ablation market through a distribution deal with Merit Medical, bringing the ViaVerte system to a chronic back pain category that Boston Scientific has been building – and that a $1.56bn growth trajectory is making increasingly hard to ignore.
Medtech Insight - March 26, 2026

Beauty M&A Glowing Up? Lauder, Puig In Merger Talks As Unilever Eyes Offloading Food Brands
Estee Lauder and Puig Brands confirm they are “in discussions regarding a potential business combination.” Unilever confirms offer for its foods business from McCormick & Co.
HBW Insight - March 26, 2026

Execs On The Move: March 16–20, 2026
An interactive look at recent executive-level company changes and promotions in the medical device and diagnostics industries.
Medtech Insight - March 26, 2026

Sandoz Springs Into Germany And Switzerland With A New Antihistamine Nasal Spray
Building on its comprehensive allergy care portfolio, Sandoz will offer patients with seasonal rhinitis a generic version of Viatris’ Dymista nasal spray.
Generics Bulletin - March 26, 2026

Anavex Not Giving Up On Alzheimer’s Drug After EU Rejection
The firm looks to have few options left in the European Union after the regulator’s rejection, but still hopes the US FDA is open to a future filing of blarcamesine.
Scrip - March 26, 2026

Aeon Gains FDA Clarity On Botox Biosimilar Path
FDA feedback following a January type 2a meeting supports Aeon’s analytical strategy for its Botox biosimilar, providing a clearer roadmap to complete comparability work in 2026 and shaping the next phase of regulatory engagement.
Generics Bulletin - March 26, 2026

Yoshindo Builds In-House Biosimilars Capacity With Cytiva Support
Cytiva’s FlexFactory deal with Yoshindo will establish domestic biosimilar manufacturing in Japan by 2028, as the firm pivots from JV-led development toward in-house production amid growing demand and policy support for lower-cost biologics.
Generics Bulletin - March 26, 2026

Executives On The Move: Alphamab Oncology Gets A New CFO From AstraZeneca
Recent moves in the industry include changes at the top at Mestag Therapeutics, Atossa Therapeutics and Kaida BioPharma, plus Alchemab Therapeutics gets a new CBO from Sanofi.
Scrip - March 26, 2026

NHS Staff Lack Basic Training For EPRs: Report
Adoption of electronic patient records is high in the NHS, but staff often struggle to use them effectively, according to a survey from the Health Foundation.
Medtech Insight - March 26, 2026

Midterm Swiss-EU Medtech MRA Still On Track After Bilaterals III
Renewal of the Swiss-EU Mutual Recognition Agreement for medical devices may still be a year or two away, but momentum towards ratification was maintained in March when Swiss and EU political leaders signed the final outstanding agreements of the Bilaterals III sectoral agreements.
Medtech Insight - March 26, 2026

Biogen Added To Alteogen’s Long List Of Partners
Following a deal with Tesaro in January, Alteogen inks another global out-licensing agreement for its subcutaneous delivery enabling platform technology, this time with Biogen.
Scrip - March 26, 2026

Thorne’s Picture Of Dietary Supplement Personalization: ‘Meet Them On Their Journey’
“What they want when they think about personalization, is that you meet them on their journey, where they are on their terms. That's what personalization is. How do brands do that? You can't do that by just broadcasting an ad,” CEO Colin Watts says.
HBW Insight - March 26, 2026